Protein Sciences
Protein Sciences Corporation is a biotech company based in Meriden, Connecticut. The company develops and produces vaccines and biopharmaceuticals for use against influenza and other diseases. Protein Sciences has developed a novel method for vaccine production, using a genetically modified baculovirus that is allowed to reproduce in insect cells.[1][2] This method reduces the lead time for vaccine production to six to eight weeks, considerably shorter than the conventional, egg-based, method.[3] The company has applied for a Biologic License Application with the U.S. Food and Drug Administration (FDA) for Flublok, their seasonal influenza vaccine.[4] [5] On Jan 17, 2013, Protein Sciences announced that the U.S. Food and Drug Administration had approved Flublok influenza vaccine for use in people 18-49 years old. Since then, Flublok's age indication has been expanded to all adults 18 and older as of October 29, 2014. Flublok is currently available. [6][7]
References
- ↑ Journal of the American Medical Association, Vol. 297:Safety and Immunogenicity of a Baculovirus-Expressed Hemagglutinin Influenza Vaccine
- ↑ The NIH Biomedical Research Response to Influenza
- ↑ NBC Connecticut: Swine Flu Vaccine Could Be Ready in 6 Weeks
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Flublok, (Influenza Vaccine, Recombinant Hemagglutinin), Briefing Document, FDA Vaccines and Related Biological Products Advisory Committee Meeting, November 19, 2009
- ↑ Andrew Pollack, "Rapidly Produced Flu Vaccine Wins F.D.A. Approval", The New York Times, January 16, 2013
- ↑ FDA press release
